PharmaBlock Sciences (Nanjing), Inc.

300725

CNE1000035K5

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
32.89 ^CNY	-1.94%		-5.73%	-16.25%

Apr. 24	PharmaBlock Proposes Final Dividend for 2023	CI
Apr. 23	PharmaBlock Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Pharmablock Sciences, Inc. Approves Election of Jie Yuanping and Wu Juanjuan as Non-Independent Directors

May 15, 2023 at 03:33 pm EDT

PharmaBlock Sciences (Nanjing), Inc. at its AGM held on May 12, 2023 approved election of Jie Yuanping and Wu Juanjuan as non-independent directors.

Latest news about PharmaBlock Sciences (Nanjing), Inc.

PharmaBlock Proposes Final Dividend for 2023	Apr. 23	CI
PharmaBlock Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 22	CI
Tranche Update on PharmaBlock Sciences, Inc.'s Equity Buyback Plan announced on October 31, 2023.	Apr. 01	CI
Tranche Update on PharmaBlock Sciences, Inc.'s Equity Buyback Plan announced on October 31, 2023.	Apr. 01	CI
Tranche Update on PharmaBlock Sciences, Inc.'s Equity Buyback Plan announced on October 31, 2023.	Jan. 02	CI
PharmaBlock Sciences, Inc Opens HPAPI GMP Facility at Zhejiang Manufacturing Site	Dec. 26	CI
PharmaBlock Sciences, Inc.(SZSE:300725) dropped from Shenzhen Stock Exchange Component A Share Index	Dec. 11	CI
PharmaBlock Sciences, Inc.(SZSE:300725) dropped from Shenzhen Stock Exchange Component Index	Dec. 11	CI
PharmaBlock Sciences, Inc. announces an Equity Buyback for CNY 40 million worth of its shares.	23-10-30	CI
PharmaBlock Sciences, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
PharmaBlock Sciences, Inc. authorizes a Buyback Plan.	23-10-29	CI
PharmaBlock Sciences, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-14	CI
Pharmablock Sciences, Inc. Announces Final Dividend on Share A for 2022, Payable in June 13, 2023	23-06-06	CI
Pharmablock Sciences, Inc. Approves Election of Jie Yuanping and Wu Juanjuan as Non-Independent Directors	23-05-15	CI
Pharmablock Sciences, Inc. Approves Final Cash Dividend for the Year 2022	23-05-15	CI
PharmaBlock Sciences, Inc. Proposes Final Cash Dividend for the Year 2022	23-04-24	CI
PharmaBlock Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-21	CI
PharmaBlock Opens New R&D Facility in Pennsylvania	23-03-27	CI
PharmaBlock Sciences, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
PharmaBlock Sciences, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-12	CI
Pharmablock Sciences, Inc. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on June 13, 2022	22-06-07	CI
PharmaBlock Approves cash dividend for the year of 2021	22-05-20	CI
Pharmablock Sciences, Inc. Proposes Final Cash Dividend for the Year 2021	22-04-29	CI
PharmaBlock Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
PharmaBlock Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-28	CI

Chart PharmaBlock Sciences (Nanjing), Inc.

Duration

Period

Chart PharmaBlock Sciences (Nanjing), Inc.

More charts

PharmaBlock Sciences Nanjing Inc is a company mainly engaged in design, synthesis and sales of pharmaceutical molecular building blocks. The Company's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The Company is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.

Sector

Pharmaceuticals

Calendar

2024-05-27 - Extraordinary Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for PharmaBlock Sciences (Nanjing), Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

32.89 CNY

Average target price

40 CNY

Spread / Average Target

+21.62%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARMABLOCK SCIENCES (NANJING), INC.	-16.25%	906M
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals

PharmaBlock Sciences (Nanjing), Inc.

Equities

300725

CNE1000035K5

Pharmaceuticals

Pharmablock Sciences, Inc. Approves Election of Jie Yuanping and Wu Juanjuan as Non-Independent Directors

Latest news about PharmaBlock Sciences (Nanjing), Inc.

Chart PharmaBlock Sciences (Nanjing), Inc.

Company Profile

Income Statement Evolution

Ratings for PharmaBlock Sciences (Nanjing), Inc.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals